Hemiasterlin analog HTI-286 effect on docetaxel-resistant prostate cancer cell line

Download

Analysis of prostate cancer LNCaP cells treated with the chemotherapeutic agent docetaxel or the hemiasterlin analog HTI-286. Like docetaxel, HTI-286 disrupts microtubule dynamics. But unlike docetaxel, HT-286 exhibits reduced multidrug resistance.

Cancer Type: Prostate Cancer

GPL: 3877

Number of Genes with Data: 893

Number Observations: 12

Number Outputs: 1

Imbalanced Ratio: 1

Default Task: Classification